Signoretti Lab (@labsignoretti) 's Twitter Profile
Signoretti Lab

@labsignoretti

ID: 1234649600583229441

calendar_today03-03-2020 01:20:13

58 Tweet

157 Takipçi

33 Takip Edilen

Signoretti Lab (@labsignoretti) 's Twitter Profile Photo

We are looking for a JUNIOR PATHOLOGIST (at least 1 year of residency training) to join our group and lead one of our translational efforts in kidney cancer. Please contact us if you are interested and willing to spend at least 2 years in the lab.

Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

🟢 Outstanding presentation at #KCRS24 ROHIT MEHRA 🟠 Role of Pathologist in Kidney Cancer Diagnostics and Research 🟠 Highlighting the morphologic diversity in renal tumors and its diagnostic implications. 🟠 Emphasis on understanding mechanisms to improve patient care.

🟢 Outstanding presentation at #KCRS24 <a href="/drmehrarohit/">ROHIT MEHRA</a> 
🟠 Role of Pathologist in Kidney Cancer Diagnostics and Research
🟠 Highlighting the morphologic diversity in renal tumors and its diagnostic implications.
🟠 Emphasis on understanding mechanisms to improve patient care.
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Sarcomatoid RCC #kidneycancer : Diagnostic Updates and Therapeutic Implications. Comprehensive talk by Sabina Signoretti Brigham and Women's Hospital 👉epigenomics, genetics and inflammed phenotype of Sarcomatoid RCC & Rx implications #KCRS24 KidneyCAN Toni Choueiri, MD Talal El Zarif, MD OncoAlert

Sarcomatoid RCC #kidneycancer : Diagnostic Updates and Therapeutic Implications. Comprehensive talk by <a href="/SabinaSign16728/">Sabina Signoretti</a> <a href="/BrighamWomens/">Brigham and Women's Hospital</a> 👉epigenomics, genetics and inflammed phenotype of Sarcomatoid RCC &amp; Rx implications #KCRS24 <a href="/kidneycan/">KidneyCAN</a> <a href="/DrChoueiri/">Toni Choueiri, MD</a> <a href="/TalalZarif1/">Talal El Zarif, MD</a> <a href="/OncoAlert/">OncoAlert</a>
Renee Maria Saliby (@reneesaliby) 's Twitter Profile Photo

Kicking off the Trials in Progress session with #ARCITECT evaluating Botensilimab+Balstilimab for pts with mRCC A trial that aims to "raise the tail" and a fantastic presentation by Michael Serzan, MD #KCRS24 KidneyCAN OncoAlert

Kicking off the Trials in Progress session with #ARCITECT evaluating Botensilimab+Balstilimab for pts with mRCC

A trial that aims to "raise the tail" and a fantastic presentation by <a href="/MikeSerzanMD/">Michael Serzan, MD</a> 

#KCRS24 <a href="/kidneycan/">KidneyCAN</a> <a href="/OncoAlert/">OncoAlert</a>
Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

Brilliant insights from Tom Powles Barts Cancer Institute (Queen Mary). Excellent use of Twitter polls to reconcile tough clinical scenarios (eg IO rechallenge following adj pembro). Shocking to hear rates of IO receipt in real world series - great point from Tom - use the best tx first. Toni Choueiri, MD

Brilliant insights from <a href="/tompowles1/">Tom Powles</a> <a href="/QMBCI/">Barts Cancer Institute (Queen Mary)</a>. Excellent use of Twitter polls to reconcile tough clinical scenarios (eg IO rechallenge following adj pembro). Shocking to hear rates of IO receipt in real world series - great point from Tom - use the best tx first. <a href="/DrChoueiri/">Toni Choueiri, MD</a>
KidneyCAN (@kidneycan) 's Twitter Profile Photo

#KCRS24 Session 8: Rapid Abstract Presentations are underway! Tertiary Lymphoid Structures in Sarcomatoid RCC Nick Salgia Brain-Specific Tropism in mRCC Roy Elias Latino Ethnicity & Gut Microbiome in mRCC Regina Barragan-Carrillo #KidneyCancer #AcceleratingCures

#KCRS24 Session 8: Rapid Abstract Presentations are underway!

Tertiary Lymphoid Structures in Sarcomatoid RCC <a href="/NickSalgia/">Nick Salgia</a> 
Brain-Specific Tropism in mRCC <a href="/rmelias2/">Roy Elias</a> 
Latino Ethnicity &amp; Gut Microbiome in mRCC <a href="/ReginaBarCar/">Regina Barragan-Carrillo</a> 

#KidneyCancer #AcceleratingCures
Razan Mohanna (@rzn_mh) 's Twitter Profile Photo

Wrapping #kcrs24! Started my day with rock the run 5k and finished it with insightful discussions and inspiring moments. So glad to be part of kidney cancer research but also part of a great team along the way of curing this cancer!

Wrapping #kcrs24! 
Started my day with rock the run 5k and finished it with insightful discussions and inspiring moments. So glad to be part of kidney cancer research but also part of a great team along the way of curing this cancer!
Tom Powles (@tompowles1) 's Twitter Profile Photo

Phase 1/2 Design of the HIF2a inhibitor NKT2152-101 showed response rate of 20% with an ‘in class’ toxicity profile #ESMO24 . The long half like makes it distinct and there in now a dose to take to randomised trials. Advantages over belzurifan are unclear. 2 doses being pursued.

Phase 1/2 Design of the HIF2a inhibitor NKT2152-101 showed response rate of 20% with an ‘in class’ toxicity profile #ESMO24 . The long half like makes it distinct and there in now a dose to take to randomised trials. Advantages over belzurifan are unclear. 2 doses being pursued.
KidneyCAN (@kidneycan) 's Twitter Profile Photo

#KCRS25 Oral Abstract: berkay şimşek🌻 Brigham and Women's Hospital links CD163+ macrophages in RCC tumors to better outcomes with nivolumab. A potential new target for immunotherapy. Read all the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25 #AcceleratingCures

#KCRS25 Oral Abstract: <a href="/simsek_berkay_/">berkay şimşek🌻</a> <a href="/BrighamWomens/">Brigham and Women's Hospital</a> links CD163+ macrophages in RCC tumors to better outcomes with nivolumab. A potential new target for immunotherapy.

Read all the abstracts: bit.ly/AbstractsKCRS25
Register: bit.ly/RegisterKCRS25

#AcceleratingCures